- GILD, GIS Ticker
- 🇩🇪 XETRA, 🇩🇪 F, 🇺🇸 NASDAQ Exchange
- 11,000 Employees
- 💊 Health Care Sector
- 🧪 Biotechnology Industry
- Daniel O'Day CEO
Financial statements — Gilead Sciences
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
25B | 22B | 22B | 26B | 30B |
| Cost Of Revenue |
|
4.6B | 4.7B | 4.9B | 4.4B | 4.3B |
| Gross Profit |
|
20B | 18B | 17B | 22B | 26B |
| Research and Development |
|
5B | 9.1B | 5B | 3.7B | 5.1B |
| Selling General and Admin |
|
5.2B | 4.4B | 4.1B | 3.9B | 3.4B |
| Operating Expense |
|
21B | 18B | 14B | 12B | 13B |
| Operating Income |
|
4.1B | 4.3B | 8.2B | 14B | 18B |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
4.1B | 4.3B | 8.2B | 14B | 18B |
| Interest Income |
|
980M | 1M | 1.1B | 1.1B | 960M |
| Pretax Income |
|
1.7B | 5.2B | 7.8B | 14B | 17B |
| Income Tax |
|
1.6B | -200M | 2.3B | 8.9B | 3.6B |
| Minority Interest |
|
-34M | -22M | 5M | 16M | -13M |
| Net Income |
|
120M | 5.4B | 5.5B | 4.6B | 14B |
| Net Income Basic |
|
120M | 5.4B | 5.5B | 4.6B | 14B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
7.4B | 24B | 31B | 26B | 12B |
| Short term investments |
|
2B | 1.4B | 740M | 1B | 1.6B |
| Receivables |
|
4.9B | 3.6B | 3.3B | 3.9B | 4.5B |
| Inventory |
|
1.7B | 920M | 810M | 800M | 1.6B |
| Other current assets |
|
2B | 1.4B | 740M | 1B | 1.6B |
| Current assets |
|
16B | 30B | 36B | 32B | 20B |
| Long term investments |
|
52B | 31B | 28B | 38B | 37B |
| Property plant equipment |
|
5B | 4.5B | 4B | 3.3B | 2.9B |
| Goodwill |
|
8.1B | 4.1B | 4.1B | 4.2B | 1.2B |
| Intangible assets |
|
33B | 14B | 16B | 17B | 9B |
| Other assets |
|
5.5B | 7.4B | 2.6B | 2.7B | 2.6B |
| Total assets |
|
68B | 62B | 64B | 70B | 57B |
| Accounts payable |
|
840M | 710M | 790M | 810M | 1.2B |
| Current long term debt |
|
2.8B | 2.5B | 2.7B | 0 | 0 |
| Other current liabilities |
|
7.8B | 6.5B | 7.1B | 11B | 8B |
| Total current liabilities |
|
11B | 9.8B | 11B | 12B | 9.2B |
| Long term debt |
|
29B | 22B | 25B | 31B | 26B |
| Other liabilities |
|
10B | 7.1B | 7B | 7.4B | 2B |
| Minority Interest |
|
19M | 130M | 150M | 59M | 480M |
| Total Liabilities |
|
50B | 39B | 42B | 50B | 38B |
| Common stock |
|
1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Retained earning |
|
14B | 19B | 19B | 19B | 18B |
| Treasury stock |
|
0 | 0 | 0 | 0 | 0 |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
18B | 23B | 21B | 20B | 19B |
| Net tangible assets |
|
-23B | 4.6B | 1.5B | -820M | 8.7B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
120M | 5.4B | 5.5B | 4.6B | 14B |
| Depreciation |
|
1.5B | 1.4B | 1.4B | 1.3B | 1.2B |
| Changes in receivables |
|
1.3B | 260M | -520M | -660M | -1.3B |
| Changes in inventories |
|
760M | 110M | 13M | -790M | -370M |
| Cash change |
|
-17B | -6.6B | 4.8B | 14B | -2.7B |
| Cash flow |
|
8.2B | 9.1B | 8.4B | 12B | 17B |
| Capital expenditures |
|
-650M | -830M | -920M | -590M | -750M |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
-15B | -7.8B | 14B | -16B | -12B |
| Dividends paid |
|
3.4B | • | • | • | • |
| Net borrowings |
|
22B | -1.2B | -4.4B | 3.6B | 13B |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
770M | -7.6B | -12B | 3.4B | -9.3B |
| Exchange rate effect |
|
• | • | • | • | • |
Analyst Recommendations
This chart is a recommendation for investors. To provide forecasts, analysts and brokers use companies' public financial reports and speak with their employees and clients. The end result is a solution that's marked on the chart, which shows analysts' opinions at different periods of time. Move your cursor to track on what the dates the recommendations changed.
Investors shouldn't only follow analyst recommendations. Forecasts should be used to supplement existing strategies and plans. Trading based on a recommendation chart is is considered bad practice. Analyst reports should only be used in conjunction with your own analytics.
It develops and implements innovative methods of treatment and prevention of severe diseases. The main research focuses on the fight against HIV and AIDS, cancer, hepatitis B and C, that is, specializes mainly in antiviral drugs. New types of treatments for Hematology, liver diseases, inflammatory and infectious diseases are also being produced, including various types of flu virus, including Harvoni and Sovaldi. In addition to the therapeutic direction, systems of specific care for patients with a severe form of the disease are being developed. Serial production of new drugs is concentrated in the regions where the problem of the spread of deadly diseases is most urgent - North and South Africa, Europe, and Asia.
The founder of the company, tried to «recruit» Warren Buffett as an investor and a member of the Board of Directors, but was unsuccessful. A year ago, The Times reported that this «American pharmaceutical firm used a controversial tax loophole to shift almost 20 billion euros of profits through an Irish legal entity in just two years.»